SINTX Technologies raises $5 million through private placement

SINTX Technologies Inc. (NASDAQ: SINT) completed a private placement raising approximately $5 million in capital, according to a company statement. The biomaterials company issued 1,882,845 shares of common stock to institutional and accredited investors at $2.39 per share, generating $4.5 million in gross proceeds before fees.

The private placement includes Class A and Class B common stock purchase warrants. Both warrant classes allow investors to purchase up to 1,882,845 additional shares at $2.14 per share. Class A warrants expire five years from issuance, while Class B warrants expire in two years. The warrants are exercisable immediately.

The company also raised $500,000 through its at-the-market offering program, bringing total recent equity capital to approximately $5 million. SINTX plans to use proceeds for general corporate purposes, including working capital, commercialization activities, business development initiatives and strategic opportunities.

The offering closed on June 3, 2026, subject to customary closing conditions. The securities were offered under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, without registration under federal or state securities laws.

SINTX has agreed to file registration statements with the Securities and Exchange Commission covering resale of the shares and underlying warrant shares.

"We believe this transaction strengthens our balance sheet and enhances our ability to pursue our strategic objectives while continuing to advance the development and commercialization of our silicon nitride technology platform," said Eric Olson, chairman and chief executive officer.

The Salt Lake City-based company develops silicon nitride biomaterials and devices for medical applications.

You May Also Be Interested In

• Forbright completes $142.2 million IPO on Nasdaq
• BIG3 Basketball to go public via Graf Global merger at $290 million
• FDA approves Merck's KEYTRUDA and WELIREG combination for kidney cancer